Cisler JM, Koster EH. Mechanisms of attentional biases towards threat in anxiety disorders: an integrative review. Clin Psychol Rev. 2010;30(2):203–16.
Stein DJ, Scott KM, de Jonge P, Kessler RC. Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues Clin Neurosci. 2017;19(2):127–36.
Article PubMed PubMed Central Google Scholar
Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327–35.
Article PubMed PubMed Central Google Scholar
Baxter AJ, Vos T, Scott KM, Ferrari AJ, Whiteford HA. The global burden of anxiety disorders in 2010. Psychol Med. 2014;44(11):2363–74.
Article CAS PubMed Google Scholar
Yang X, Fang Y, Chen H, Zhang T, Yin X, Man J, et al. Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019. Epidemiol Psychiatr Sci. 2021;30: e36.
Article PubMed PubMed Central Google Scholar
Konnopka A, König H. Economic burden of anxiety disorders: a systematic review and meta-analysis. Pharmacoeconomics. 2020;38(1):25–37.
Santomauro DF, Herrera AMM, Shadid J, Zheng P, Ashbaugh C, Pigott DM, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700–12.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013.
Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci. 2017;19(2):93–107.
Article PubMed PubMed Central Google Scholar
Blier P, de Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology. 1999;21(2 Suppl):91S-S98.
Article CAS PubMed Google Scholar
Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem. 1994;40(2):288–95.
Article CAS PubMed Google Scholar
Kraus C, Castrén E, Kasper S, Lanzenberger R. Serotonin and neuroplasticity—links between molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev. 2017;77:317–26.
Article CAS PubMed Google Scholar
Lowry CA, Johnson PL, Hay-Schmidt A, Mikkelsen J, Shekhar A. Modulation of anxiety circuits by serotonergic systems. Stress. 2005;8(4):233–46.
Article CAS PubMed Google Scholar
Grossman L, Utterback E, Stewart A, Gaikwad S, Chung KM, Suciu C, et al. Characterization of behavioral and endocrine effects of LSD on zebrafish. Behav Brain Res. 2010;214(2):277–84.
Article CAS PubMed Google Scholar
Páleníček T, Hliňák Z, Bubeníková-Valešová V, Novák T, Horáček J. Sex differences in the effects of N, N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition. Progress Neuro-Psychopharmacol Biol Psychiatry. 2010;34(4):588–96.
Lewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, et al. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep. 2023;42(3): 112203.
Article CAS PubMed PubMed Central Google Scholar
Altemus M, Sarvaiya N, Neill EC. Sex differences in anxiety and depression clinical perspectives. Front Neuroendocrinol. 2014;35(3):320–30.
Article PubMed PubMed Central Google Scholar
McLean CP, Anderson ER. Brave men and timid women? A review of the gender differences in fear and anxiety. Clin Psychol Rev. 2009;29(6):496–505.
Spigner C, Hawkins WE, Loren W. Gender differences in perception of risk associated with alcohol and drug use among college students. Women Health. 1993;20(1):87–97.
Article CAS PubMed Google Scholar
Thiessen MS, Walsh Z, Bird BM, Lafrance A. Psychedelic use and intimate partner violence: the role of emotion regulation. J Psychopharmacol. 2018;32(7):749–55.
Kettner H, Mason NL, Kuypers KPC. Motives for classical and novel psychoactive substances use in psychedelic polydrug users. Contemp Drug Problems. 2019;46(3):304–20.
Cameron LP, Nazarian A, Olson DE. Psychedelic microdosing: prevalence and subjective effects. J Psychoactive Drugs. 2020;52(2):113–22.
Article PubMed PubMed Central Google Scholar
Mittman SM, Geyer MA. Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol. Psychopharmacology. 1991;105(1):69–76.
Article CAS PubMed Google Scholar
Mittman SM, Geyer MA. Effects of 5HT-1A agonists on locomotor and investigatory behaviors in rats differ from those of hallucinogens. Psychopharmacology. 1989;98(3):321–9.
Article CAS PubMed Google Scholar
Krebs KM, Geyer MA. Cross-tolerance studies of serotonin receptors involved in behavioral effects of LSD in rats. Psychopharmacology. 1994;113(3–4):429–37.
Article CAS PubMed Google Scholar
Geyer MA, Gordon J, Adams LM. Behavioral effects of xylamine-induced depletions of brain norepinephrine: interaction with LSD. Pharmacol Biochem Behavior. 1985;23(4):619–25.
Adams LM, Geyer MA. A proposed animal model for hallucinogens based on LSD’s effects on patterns of exploration in rats. Behav Neurosci. 1985;99(5):881–900.
Article CAS PubMed Google Scholar
Adams LM, Geyer MA. LSD-induced alterations of locomotor patterns and exploration in rats. Psychopharmacology. 1982;77(2):179–85.
Article CAS PubMed Google Scholar
Geyer MA, Light RK, Rose GJ, Petersen LR, Horwitt DD, Adams LM, et al. A characteristic effect of hallucinogens on investigatory responding in rats. Psychopharmacology. 1979;65(1):35–40.
Article CAS PubMed Google Scholar
Conway CN, Baker LE. Lysergic acid diethylamide produces anxiogenic effects in the rat light/dark test and elevated plus maze. Psi Chi J Psychol Res. 2022;27(3):197–204.
De Gregorio D, Inserra A, Enns JP, Markopoulos A, Pileggi M, El Rahimy Y, et al. Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. Neuropsychopharmacology. 2022;47:1188–98.
Article PubMed PubMed Central Google Scholar
Strajhar P, Schmid Y, Liakoni E, Dolder PC, Rentsch KM, Kratschmar DV, et al. Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. J Neuroendocrinol. 2016. https://doi.org/10.1111/jne.12374.
Tronche F, Kellendonk C, Kretz O, Gass P, Anlag K, Orban PC, et al. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genetics. 1999;23(1):99–103.
Article CAS PubMed Google Scholar
Boyle MP, Kolber BJ, Vogt SK, Wozniak DF, Muglia LJ. Forebrain glucocorticoid receptors modulate anxiety-associated locomotor activation and adrenal responsiveness. J Neurosci. 2006;26(7):1971–8.
Article CAS PubMed PubMed Central Google Scholar
De Gregorio D, Posa L, Ochoa-Sanchez R, McLaughlin R, Maione S, Comai S, et al. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT(1A), D(2) and TAAR(1) receptors. Pharmacol Res. 2016;113(Pt A):81–91.
Aghajanian GK. Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli. Brain Res. 1980;186(2):492–8.
Article CAS PubMed Google Scholar
Inserra A, De Gregorio D, Rezai T, Lopez-Canul MG, Comai S, Gobbi G. Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: an in vivo electrophysiology study in male mice. J Psychopharmacol. 2021;35(4):469–82.
Article CAS PubMed PubMed Central Google Scholar
Bershad AK, Schepers ST, Bremmer MP, Lee R, de Wit H. Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol Psychiatry. 2019;86(10):792–800.
Comments (0)